EPO Patents = 1

Forward Citations = 7

Loading Chart...

3 inventors (with patents filed for the assignee):

Hong Hoi Ting (5 out of 5 patents)

Chung Lim Wong (5 out of 5 patents)

Wenhua Huang (2 out of 4 patents)

5 patents: Sort by Forward Citations

1. 12083193 - Anti-Her2 nanobody and coding sequence and use thereof (2024-09-10),

2. 11642418 - Use of radiolabeled nanobody in prognosis and diagnosis of cancer (2023-05-09),

3. 11517632 - Anti-Her2 single chain antibody and coding sequence and use thereof (2022-12-06),

4. 11466085 - Anti-PD-L1 nanobody, coding sequence and use thereof (2022-10-11),

5. 10556954 - Anti-PD-L1 nanobody, coding sequence and use thereof (2020-02-11),

Nanomab Technology Limited is a leading biotechnology company specializing in the development of innovative nanomedicines for targeted cancer therapy. Our proprietary platform enables the design and production of highly specific antibodies for precision medicine applications. With a focus on personalized oncology treatments, Nanomab is dedicated to improving patient outcomes and advancing the field of precision medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

5 Patents

#572 in Hong Kong

#4,563 in China

Hong Kong, China

Nanomab Technology Limited

Forward Citations = 7

3 inventors:

Hong Hoi Ting (5 out of 5 patents)

Chung Lim Wong (5 out of 5 patents)

Wenhua Huang (2 out of 4 patents)

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com